Flunitrazepam is marketed as a potent hypnotic, sedative, anticonvulsant, anxiolytic, amnestic, and skeletal muscle relaxant drug most commonly known as Rohypnol. An intermediate acting benzodiazepine, flunitrazepam is prescribed for the treatment of severe insomnia, marketed by Roche. In general, the prescription of flunitrazepam as a hypnotic is intended to be for short-term treatment of chronic or severe insomniacs not responsive to other hypnotics, especially in inpatients. It is considered to be one of the most effective benzodiazepine hypnotics on a dose basis. Just as with other hypnotics, flunitrazepam should be used only on a short-term basis or in those with chronic insomnia on an occasional basis. Flunitrazepam is classed as a nitro-benzodiazepine. It is the fluorinated methylamino derivative of nitrazepam. Other nitro-benzodiazepines include nitrazepam the parent compound and clonazepam, the chlorinated derivative.
Contributions by MrADHD, Kazlow101, and 184.108.40.206.